The Filing Desk

Firefly Neuroscience vs SOPHiA GENETICS

Firefly Neuroscience AIFF · SOPHiA GENETICS SOPH · Health Care Technology

SOPHiA GENETICS reported revenue of $77 million in fiscal 2025, 70.3 times Firefly Neuroscience's $1 million in fiscal 2025. Firefly Neuroscience's revenue grew 957.4% in its latest year, and SOPHiA GENETICS's grew 18.6%. Firefly Neuroscience had an operating margin of -775.5%, against -91.8% at SOPHiA GENETICS.

Side by side

Firefly NeuroscienceSOPHiA GENETICS
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$1M$77M
Revenue growth957.4%18.6%
Revenue growth a year, last 5 years−39.8%22.2%
Gross margin56.5%67.4%
Operating margin−775.5%−91.8%
Net margin−1,741.0%−102.2%
Free cash flow—−$36M
Free cash flow margin—−47.2%
Return on capital−411.7%−207.1%
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count90.1%2.2%
Last close$0.80$6.68
P/E at the last close——
Insider trades, last 12 months—bought $99,000, sold $4.2 million
Piotroski F-score4 of 92 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Firefly NeuroscienceSOPHiA GENETICS
Operating margin
Percent of revenue
Firefly NeuroscienceSOPHiA GENETICS
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Firefly NeuroscienceSOPHiA GENETICS

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Firefly Neuroscience and SOPHiA GENETICS pages.